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Abstract
Background: There is a small, but growing body of literature highlighting inequities in GP practice
prescribing rates for many drug therapies. The aim of this paper is to further explore the equity of
prescribing for five major CHD drug groups and to explain the amount of variation in GP practice
prescribing rates that can be explained by a range of healthcare needs indicators (HCNIs).
Methods: The study involved a cross-sectional secondary analysis in four primary care trusts
(PCTs 1–4) in the North West of England, including 132 GP practices. Prescribing rates (average
daily quantities per registered patient aged over 35 years) and HCNIs were developed for all GP
practices. Analysis was undertaken using multiple linear regression.
Results: Between 22–25% of the variation in prescribing rates for statins, beta-blockers and
bendrofluazide was explained in the multiple regression models. Slightly more variation was
explained for ACE inhibitors (31.6%) and considerably more for aspirin (51.2%). Prescribing rates
were positively associated with CHD hospital diagnoses and procedures for all drug groups other
than ACE inhibitors. The proportion of patients aged 55–74 years was positively related to all
prescribing rates other than aspirin, where they were positively related to the proportion of
patients aged >75 years. However, prescribing rates for statins and ACE inhibitors were negatively
associated with the proportion of patients aged >75 years in addition to the proportion of patients
from minority ethnic groups. Prescribing rates for aspirin, bendrofluazide and all CHD drugs
combined were negatively associated with deprivation.
Conclusion: Although around 25–50% of the variation in prescribing rates was explained by
HCNIs, this varied markedly between PCTs and drug groups. Prescribing rates were generally
characterised by both positive and negative associations with HCNIs, suggesting possible inequities
in prescribing rates on the basis of ethnicity, deprivation and the proportion of patients aged over
75 years (for statins and ACE inhibitors, but not for aspirin).
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The aim of this paper is to provide data on the equity of
general medical practitioner (GP) prescribing rates for
coronary heart disease (CHD) drugs. Since CHD repre-
sents a major cause of premature mortality in the Western
world, it is vital that those populations with the highest
need for CHD drugs actually receive them. Whilst there is
a large literature on inequities in the provision of a
number of other health care services and treatments, the
equity of GP practice prescribing has received little atten-
tion. Therefore, this study was an attempt initiate the
development of an evidence-base and to provide data on
the equity of GP practice prescribing rates.
Conceptualisation and definition of the equity of 
prescribing
There are large literatures around how to define, opera-
tionalise and measure equity in relation to health care
services [1-3], although equity is generally taken to mean
'fair' or 'just'. Equity has been divided into three domains:
equal access to health care for people in equal need; equal
treatment for people in equal need; and equal outcomes for
people in equal need [1]. Whilst this is a simplification of
the nature of equity, it is useful in delineating the various
domains in which inequities may arise.
The current paper is focussed around the equal prescrib-
ing (i.e. equal treatment) for people in equal need. Using
the example of the current study, an analysis of equity
would assess the differences in prescribing rates provided
to the population of one GP practice compared to another
GP practice, weighted to take account of the levels of need
for CHD drugs in their patient populations. Therefore, it
would be equitable to have higher prescribing rates for
populations with higher levels of health care need and
lower prescribing rates for populations with lower levels
of health care need. However, it would be inequitable to
have higher prescribing rates for populations with lower
levels of health care need and lower prescribing rates for
populations with higher levels of health care need. The
identification of populations where prescribing was
deemed inequitable could then be targeted for further
resources aimed at redressing the balance between pre-
scribing rates and health care need.
Previous research on the equity of GP practice prescribing
A recent paper by the authors questioned the equity of GP
practice prescribing rates for a range of CHD drugs[4] and
highlighted the contemporary relevance of the 'inverse
care law'[5] in the context of GP prescribing. That paper
presented the findings of bivariate correlations between
prescribing rates and healthcare needs indicators
(HCNIs). One of the inherent problems with bivariate
analysis is that prescribing rates are likely to be associated
with a number of HCNIs. Therefore, the purpose of this
paper is to present the findings of multivariate regression
analyses between prescribing rates and the HCNIs and
ultimately to examine the independent associations
between prescribing rates and HCNIs. In doing so, this
paper sets a benchmark for future studies aimed at assess-
ing the effectiveness of the National Service Framework
for CHD in developing CHD services commensurate with
healthcare need [6].
There is a growing body of research which has highlighted
large variations in overall prescribing rates between GP
practices, which are only partially explained by factors
other than health care need [4,7-11]. Statin prescribing
has been shown to vary between health authorities and
GPs [12-15] and between patients on the basis of gender
[13,16-18], demographics [13,19], ethnicity [20] and dep-
rivation [21]. Prescribing rates of beta-blockers have also
been found to be lower in patients aged over 75 years and
in minority ethnic groups [22,23].
Studies attempting to 'explain' the variation in statin pre-
scribing rates have been modest, with most studies
explaining around 20 per cent of the variation
[13,15,21,24]. In addition, one study explained around
40 per cent of the variation in prescribing rates for all car-
diovascular drugs [21]. The prevalence of CHD explained
12 per cent of the variation in statin prescribing in men,
and 7 per cent in women [13], deprivation explained 14
per cent [15], and a combination of nitrate prescribing
rates and population aged between 35 and 74 years
explained 18 per cent [24]. In addition, the indicative
prevalence of CHD was moderately correlated with pre-
scribing rates for statins, and was the most important var-
iable in the multiple regression model [21]. However,
characteristics of GP practices such as their training status,
the number of GPs, or their single-handed status (i.e.
whether or not they are 'lone' GPs or work in a multi-part-
ner practice) have been found to have no relationship
with prescribing rates for statins [15,24]. Therefore, the
majority of variations in statin prescribing rates in addi-
tion to prescribing rates for other CHD drugs remain
unexplained.
Context and setting for the study
The planning and provision of health care to local popu-
lations in England is now the role of primary care trusts
(PCTs). Essentially, PCTs are organisations whose main
responsibilities are around developing, commissioning
and providing services, which are targeted to the needs of
local people, and ultimately to improve the health (and
reduce health inequalities) of local people [25,26]. PCTs
have taken over these responsibilities from health author-
ities, which no longer exist [27] and are responsible for
spending 75 per cent of the overall NHS budget in Eng-
land [28].Page 2 of 11
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to as PCT1, PCT2, PCT3, and PCT4 throughout this
paper), which included 132 GP practices (PCT1 had 50
GP practices, PCT2 had 24, PCT3 had 31 and PCT4 had
27). In terms of patient populations, we excluded patients
aged under 35 years, since prevalence of CHD is particu-
larly low in this age group. In total, there were 353,897
registered patients aged over 35 year across all 4 PCTs.
Methods
In order to analyse the equity of prescribing for CHD
drugs, we firstly needed to gather data on, and then
develop rates for both GP practice prescribing and health
care need (called health care needs indicators (HCNIs) in
this paper). The data sources and methods used to
develop prescribing rates and HCNIs have been outlined
in previous papers by the authors [4,29,30], although a
brief précis will be presented here. Local Research Ethics
Committee approval was sought and granted for this
study.
Developing prescribing rates
When an NHS prescription is dispensed in primary care,
the prescription form (FP10) is sent to the Prescription
Pricing Authority (PPA) for processing. The PPA collates
these data and provides them to GP practices and PCTs in
the form of Prescribing Analysis and Cost (PACT) data.
PACT data are available for all GP practices in England,
and allow detailed interrogation in terms of drugs pre-
scribed along with their dosages, pack sizes and formula-
tions. For example, for a specific time period, we can
collect data on which statins were prescribed by a GP prac-
tice in addition to the dosages and pack sizes. This allows
for a complex and timely analysis of PACT data. Useful
critiques of PACT data can be found elsewhere [31,32].
PACT data were obtained for all GP practices in the 4 PCTs
for the 12-month period October 1999 to September
2000. These data were collected for statins, ACE-inhibi-
tors, beta-blockers, aspirin, and bendrofluazide (a full list
of drugs obtained are listed in Appendix A). These drug
groups were chosen because they represent major drug
groups recommended for the prevention (primary and
secondary) of coronary heart disease (CHD) in the United
Kingdom (UK) [6]. Using prescribing rates for aspirin was
potentially difficult, since it can also be purchased over
the counter (OTC) in community pharmacies and there-
fore may not represent the totality of aspirin use within
populations [33,34]. It has also been found that non-pre-
scription aspirin use was higher in men aged under 65
years, and also in more affluent areas [35]. Therefore,
PACT data may underestimate actual aspirin use within
the community. Nevertheless, given the importance of
aspirin within the management and prevention of CHD
[17,36,37], it was postulated that prescribing rates for
aspirin may reflect CHD prevalence within GP practice
populations, at least as well or even better than prescrib-
ing rates for the other CHD drugs.
The numerator in all prescribing rates was based on a
measure of prescription volume, as opposed to prescrip-
tion cost. The validity of using the number of prescription
items or total cost as a measure of prescribing volume has
been called into question [38,39] since it does not specify
the quantity of prescription medication (e.g. number and/
or dosage of tablets). Therefore, a measure of prescription
volume which calculates the total number of grams pre-
scribed is much more useful. The main options available
are defined daily doses (DDDs) [40,41] and Average Daily
Quantities (ADQs) [40,42,43]. The Prescribing Support
Unit website provides up to date lists of DDDs http://
www.psu.co.uk/ddds.html and ADQs http://
www.psu.ac.uk/drugs/adqind.html for all drugs for which
they have been developed. Within this study, total ADQs
were used as the unit of analysis since they represent pre-
scribing practices in the UK, as opposed to DDDs which
represent prescribing practices internationally.
The denominator was the total registered (and resident)
patient population aged over 35 years. This age group was
chosen since the prevalence of CHD is particularly low in
people aged less than 35 years [44].
Developing health care needs indicators (HCNIs)
In total, 24 HCNIs were developed for each GP practice in
this study, and all of these were entered into multiple
regression models (all HCNIs are outlined in Appendix
B). These HCNIs reflect patient demographics, ethnicity,
socio-economic status, long term limiting illness, CHD
mortality and CHD morbidity. However, the only HCNIs
discussed here are those included in the final regression
models (see Table 1).
In order to assess the equity of prescribing for CHD drugs,
we needed to develop a set of variables which measured
(or acted as proxies for) the health care need in GP prac-
tice populations. In terms of coronary heart disease
(CHD), there are a number of identifiable risk-factors, all
of which increase the risk of CHD morbidity and/or mor-
tality. However, readily available data are not available for
a number of these risk-factors, and therefore could not be
explored within this study. Nevertheless, data were avail-
able on the following risk-factors: age, gender ethnicity,
socio-economic status. Evidence on the importance of
these risk-factors for assessing health care need is pre-
sented below.
Rates of CHD related morbidity and mortality increase
dramatically with age [45,46]. For example, the preva-
lence of angina in England was 1 per cent in people agedPage 3 of 11
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although this increased to 10 per cent in those aged 55–
64 years, 16 per cent in those aged 65–74 years and 18 per
cent in those aged over 75 years [47].
Rates of CHD mortality and morbidity in the UK are gen-
erally seen to be higher for people from South-Asian
groups, than from white-English people, and much lower
for people born in the Caribbean. It has been suggested
that the mortality rate for South Asians is 50 per cent
higher than for the general population [48]. In the UK, the
standardised mortality rates for CHD in South-Asian men
was 146, compared to 100 for all men and just 46 for men
born in the Caribbean [49]. It is also recognised that there
are differences within South Asian groups, especially
between Indians, who generally experience better health,
and Pakistanis or Bangladeshis, who have generally worse
health [50-53]. However, reliable data on CHD morbidity
or mortality down to these more complex ethnic group-
ings are not readily available, and any estimates are, at
best, imprecise [50]. Nevertheless, data on the ethnic
minority profiles of GP practice populations may prove
very useful in determining the need for CHD drugs.
There is an extensive literature on socio-economic ine-
qualities in CHD mortality and morbidity [54-57]. Whilst
rates of CHD have been declining in the UK for almost 20
years, they have not been falling as fast as countries such
as Australia and the United States [46]. Declining CHD
mortality rates are only partially explained by reductions
in established cardiovascular risk factors [58-60] and it is
possible that general social and economic improvement
over time has contributed to this trend [61]. However, it is
noteworthy that these benefits have not been observed by
all of the socio-economic groups within the UK [62]. For
example, deaths from CHD in men in the highest social
class have halved in the past 20 years, but remain almost
unchanged among men in the lowest social class [60].
Between 1986 and 1992, people from the highest social
classes had a rate of 160 CHD deaths per 100,000 popu-
lation, whereas the rate for the lowest social classes was
266 per 100,000 [49]. In addition, a 22-year follow-up
study on the relationship between socioeconomic status
and CHD in middle-aged men [63] found that irrespective
of length of follow-up, lower social classes had a clearly
increased risk of fatal CHD – after 8 years they had a 69
per cent increased risk, which dropped to 67 per cent after
15 years and 59 per cent after 22 years. Therefore, socio-
economic status is significantly related to CHD mortality
and morbidity, and as such, represents an important indi-
cator of health care need for CHD drugs.
Overall, the age, ethnicity and socio-economic status are
all important factors in shaping the epidemiology of CHD
in the UK, and as such, are important variables for use in
developing the HCNIs in this study. The actual develop-
ment of HCNIs relating to these risk factors are outlined
below, in addition to additional HCNIs related more
directly to CHD morbidity and mortality.
Some HCNIs were collected directly from GP practice lists
(proportion of patients aged over 75 years and proportion
of patients aged 55–74 years), some have been calculated
for GP practices (Low Income Scheme Index (LISI) score)
[64], and others were calculated from data directly attrib-
utable to GP practices (data based on hospital episode sta-
tistics). However, due to the lack of information available
from GP practices on variables such as socio-economic
status and ethnicity (in this study, this refers to South
Asian groups) of patients, a number of HCNIs were devel-
oped which estimated this from data such as the 1991
Census and Local Authority statistics. The method of
patient weighted attribution was used to develop these
estimates using data at enumeration district level (small
Table 1: Descriptions of statistically significant variables in final regression models
Descriptor used in text and Table 4 Description
CHD HES rate 6-year crude rate of CHD hospital procedures per 1000 patients (i.e. 
proxy for CHD morbidity). Data source was the General Practice 
Research Database.
% patients aged 55–74 Proportion of patients in GP practice population aged 55–74 years. Data 
source was the individual GP practices.
% patients aged >75 Proportion of patients in GP practice population aged over 75 years. 
Data source was the individual GP practices.
LISI score Low Income Scheme Index (LISI) score which is the proportion of 
prescriptions in GP practices which were exempt from payment due to 
low income (i.e. proxy for deprivation). Data source was the individual 
GP practices.
Ethnicity Proportion of patients in GP practice population defined as South Asian. 
Data source was the 1991 Census.Page 4 of 11
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were linked to enumeration districts. Data on the enumer-
ation districts of all registered patients were then aggre-
gated for each GP practice and divided by the total
registered population in order to provide a patient-
weighted score. In this way, data from the Census were
directly applied to GP practice populations. Further infor-
mation and critiques of this method can be found else-
where [65-67]. Whilst 1991 Census data may be regarded
as rather old now (and has since been superseded by 2001
Census data), these were the only data available at the
time of the study, since GP practices do not routinely col-
lect data on the ethnicity of patients. Nevertheless, the
HCNI relating to ethnicity may be seen with caution in
this paper.
Demographic HCNIs were developed directly from GP
practice list data, and these relate to the proportion of
patients aged 55–74 years, and the proportion aged over
75 years. Both of these demographic groups are indicators
of health care need for CHD drugs [44]. The Low Income
Scheme Index (LISI) was used as a proxy for low income
since it represents the proportion of prescriptions which
are exempt from prescription charges due to low income
[64]. The proportion of patients from South Asian groups
was estimated for each GP practice using data from the
1991 census.
Data were also obtained from hospital episode statistics
(HES) on specific hospital procedures (coronary artery
bypass graft (CABG), percutaneous transluminal angi-
oplasty (PTCA), and coronary angiogram) and diagnoses
(primary diagnosis of CHD at discharge). Although HES
relate to the supply, as opposed to need for health care
services [68], it was hypothesised that in the absence of
other CHD morbidity data, they may represent a useful
proxy of CHD morbidity in GP practice populations. Due
to the low numbers of procedures and diagnoses within a
GP practice population, data were aggregated for 6 years
(1995 to 2000 inclusive). Crude rates (per 1000 patients
aged over 35 years) were calculated for CHD HES, which
represents the CHD procedures + CHD diagnoses.
As outlined in Appendix B, a number of other variables
relating to CHD mortality and morbidity were entered
into the regression models, although these were not statis-
tically significant. Indeed, as outlined in a previous paper
by the authors [4], bivariate analyses revealed that associ-
ations between prescribing rates and standardised mortal-
ity rates for CHD were often not statistically significant
and in some cases had a negative association. Therefore,
prescribing rates and CHD mortality rates do not exhibit
a strong relationship, adding to the suggestion of an ineq-
uity in prescribing rates.
Data analysis
Multiple linear regression modelling was undertaken for
each drug group in each PCT in addition to the combined
dataset. The dependent variable in each model was the
respective prescribing rate and the independent variables
were all 24 HCNIs developed in the study. The forward-
stepwise approach was taken but not slavishly adhered to
since considerations of model coherence and plausibility
were taken into account when seeking the most parsimo-
nious models. The final regression models only contained
the HCNIs which had statistically significant (p < 0.05)
independent associations with the dependent variable,
and each model was checked for collinearity and normal-
ity of residuals. Overall, for each multiple regression
model, all 24 HCNIs were entered as independent varia-
bles, and the final model included only those variables
that were statistically significant and added to the fit of the
model.
Results
Descriptive findings will be presented first, in order to
contextualise the findings from the multiple regression
analyses.
Variations in prescribing rates and health care needs 
indicators (HCNIs)
Table 2 provides details of variations between primary
care trusts (PCTs) in prescribing rates for each of the study
drug groups. PCT1 generally had the highest median pre-
scribing rates, followed by PCT2, with the lowest prescrib-
ing rates occurring in PCT3 and PCT4. The median ADQs
per patient over 35 years for all study CHD drugs com-
bined were 105 in PCT1, 93 in PCT2, 90 in PCT3, and 84
in PCT4.
PCT1 had the highest median prescribing rates for all
drugs except aspirin, where PCT4 had the highest median
rate. PCT3 had the lowest median prescribing rates for
aspirin, beta-blockers and ACE inhibitors, and PCT4 had
the lowest median prescribing rates for statins, bendroflu-
azide, and all study CHD drugs combined. The difference
between the median prescribing rates for PCT1 and PCT4
for bendrofluazide, statins and all CHD drugs was around
4, 5, and 21 ADQs per patient over 35 years. Therefore, an
average GP practice in PCT1 with 3000 registered patients
over 35 years, prescribed 12000 more ADQs for bend-
rofluazide, 15000 more ADQs for statins, and 63000
more ADQs for all study CHD drugs. In addition, a similar
GP practice in PCT1 also prescribed almost 30000 more
ADQs for ACE inhibitors than a comparably sized GP
practice in PCT3.
An initial overview of the health care needs of the PCTs
suggests that PCT4 had the highest levels of CHD related
health care needs within the study, whereas PCT1 had thePage 5 of 11
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all PCTs, had the highest proportions of patients aged
over 75 years, and the highest median score for standard-
ised mortality rates (SMR) for CHD. In contrast, PCT1
may be seen as the 'least needy' of all PCTs on the basis of
the HCNIs developed in this study. PCT1 was the least
deprived, had the lowest proportions of South Asian
groups, had the lowest median SMR and the lowest
median rate of CHD hospital procedures.
These overall descriptive findings are indicative of inequi-
table prescribing rates, whereby PCT1 had high prescrib-
ing rates and low comparative health care needs, whereas
PCT4 had low prescribing rates and high comparative
health care needs. However, these are purely descriptive
and do not take into account the multiple risk factors for
CHD or the interactions between HCNIs. Therefore, find-
ings from the multiple regression analyses are presented
below.
Multiple regression analysis
Table 3 presents the percentage of variation explained in
each of the models (i.e. R2 * 100), Table 1 presents a
description of the HCNIs included in the final regression
models and Table 4 presents details for the combined
dataset in terms of the HCNIs included in each model,
their standardised beta coefficients and their contribution
(in terms of percentage variation explained) to the total R2
of the model.
Regression models generally explained much more varia-
tion in prescribing rates in PCT2 than any other PCT. For
example, in PCT2, modelling explained around 55 per
cent of the variation in prescribing rates for ACE inhibitors
and bendrofluazide, almost 60 per cent for statins and
almost 90 per cent of variation in aspirin prescribing rates.
Multiple regression models explained around 25 to 55 per
cent of the variation in prescribing rates in the combined
dataset, around 25 to 60 per cent in PCT3, and around 40
Table 2: Variation in prescribing rates by primary care trust (PCT)
Drug group PCT1 PCT2 PCT3 PCT4
Statins Min 11.05 9.56 6.86 6.44
Max 47.23 32.12 46.60 45.76
Median 22.88 19.65 18.08 17.36
IQR 8.20 11.20 8.40 7.24
Aspirin Min 14.62 15.34 4.94 9.6
Max 44.97 46.40 46.63 45.65
Median 29.27 27.35 25.33 30.87
IQR 7.40 16.5 7.60 18.85
Beta-blockers Min 5.04 6.38 3.94 3.43
Max 23.92 29.04 23.91 26.19
Median 12.84 12.38 12.32 12.64
IQR 4.61 7.70 7.41 10.11
ACE inhibitors Min 15.47 9.85 4.20 4.69
Max 48.40 39.25 32.97 35.69
Median 26.43 19.76 16.59 19.19
IQR 8.82 11.17 9.37 11.29
Bendrofluazide Min 4.19 1.63 1.63 0.60
Max 35.61 29.55 32.90 22.91
Median 14.42 10.85 11.04 9.01
IQR 6.98 8.15 12.70 7.28
All study CHD 
drugs
Min 71.70 57.28 25.89 24.76
Max 156.82 154.21 136.64 150.68
Median 105.37 92.78 90.33 83.65
IQR 28.25 57.07 32.08 51.18Page 6 of 11
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general, and no model was derived for ACE inhibitors.
Given the reduced explanatory power of the regression
models in PCT1, when regression modelling was under-
taken for the combined dataset, the R2 values were much
lower than those for PCT2, and generally lower than those
for both PCT3 and PCT4.
In general, regression modelling explained more variation
in prescribing rates for aspirin than for the other drug
groups. Not including PCT1, regression modelling
explained between 50 and 90 per cent of the variation in
aspirin prescribing rates. Comparative percentages were
between 30 and 60 per cent for statins, 30 and 45 per cent
for beta-blockers, and 25 and 55 per cent for ACE inhibi-
tors and bendrofluazide.
Table 4 presents details of the regression models derived
for each drug group in the combined dataset. Many of the
models in Table 4 are quite similar in terms of the HCNIs
included within them, with all models (except for ACE
inhibitors) including the rate of CHD HES (positive asso-
ciation) and all models (except for aspirin) including the
proportion of patients aged between 55 and 74 years (pos-
itive association). In addition, the LISI score was included
in the models for aspirin, bendrofluazide and all CHD
drugs (negative association).
The models for statins, aspirin and ACE inhibitors also
included the proportion of patients aged over 75 years
although this indicator had a negative association with
prescribing rates for statins and ACE inhibitors, and a pos-
itive association with prescribing rates for aspirin. This
Table 3: Percentage of variation in prescribing rates explained by HCNIs
PCT1 PCT2 PCT3 PCT4 Combined
Statins 24.5 58.3 31.3 50.5 24.9
Aspirin 44.2 88.2 62.3 51.7 51.2
ACE inhibitors No Model 55.3 26.6 45.8 31.6
Beta-blockers 28.3 42.4 46.1 41.1 27.1
Bendrofluazide 15.6 53.9 40 54.5 24.1
Table 4: Regression models for combined dataset
Drug group R2 Needs indicator Beta coefficient % explained
Statins .249 CHD HES rate .350 14.7
% patients aged >75 -.240 4.2
Ethnicity -.233 3.1
% patients aged 55–74 .199 2.9
Aspirin .512 CHD HES rate .579 32.9
LISI score -.261 10.4
% patients aged >75 .347 8.2
ACE inhibitors .316 Ethnicity -.395 25.3
% patients aged >75 -.170 3.4
% patients aged 55–74 .248 2.9
Beta-blockers .271 CHD HES rate .411 19.7
% patients aged 55–74 .274 7.4
Bendrofluazide .241 LISI score -.261 13.1
CHD HES rate .171 6.6
% patients aged 55–74 .274 4.4
All CHD drugs .454 LISI score -.303 22.7
CHD HES rate .461 20.0
% patients aged 55–74 .242 2.7Page 7 of 11
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patients aged over 75 years have lower prescribing rates
for statins and ACE inhibitors, and higher prescribing
rates for aspirin.
The CHD HES rate varied considerably between models,
in terms of the amount of variation explained. For exam-
ple, it explained 33 per cent of the variation in aspirin pre-
scribing rates, 20 per cent of the variation in prescribing
rates for all CHD drugs and beta-blockers, 15 per cent of
the variation in statin prescribing rates, and 7 per cent of
the variation in prescribing rates for bendrofluazide.
The LISI score explained 23 per cent of the variation in
prescribing rates for all CHD drugs, 13 for bendrofluazide
and 10 per cent for aspirin. In addition, the proportion of
patients aged between 55 and 74 years explained between
2.5 and 7 per cent of the variation for statins, ACE inhibi-
tors, beta-blockers, bendrofluazide, and all CHD drugs.
Discussion
The rate of CHD hospital procedures (CHD HES)
explained some of the variation in prescribing rates and
therefore, prescribing rates in these instances were posi-
tively related to health care need (i.e. equitable). These
findings concur with other studies whereby positive rela-
tionships were found between rates of PTCAs and both
aspirin prescribing [36] and statin prescribing [36,69,70].
These may suggest that prescribing rates are positively
related to healthcare need, although as already outlined,
HES may actually reflect supply or demand, rather than
need per se. Nevertheless, within this study, HES were the
best data available as proxies for CHD in the GP practices,
and therefore, we suggest that these prescribing rates
reflect CHD prevalence, and hence healthcare need. GP
practices in the UK are now developing CHD registers,
which may be used in the future as proxies of CHD prev-
alence, although again, these will only reflect treated
CHD, as opposed to the true prevalence of CHD in the
community.
The proportion of patients aged 55–74 years was generally
positively related to prescribing rates, suggesting that pre-
scribing rates are related to health care need, since people
in this age group have a higher prevalence of CHD [49]. A
number of studies have found that statin prescribing is
higher in this age group, than in older age groups
[13,16,17,70], with one study finding that the proportion
of patients aged 35–74 years explained just 5 per cent of
the variation in statin prescribing rates between GP prac-
tices [24].
Whilst the previous finding is not unexpected given the
higher CHD prevalence in this age group, the negative
relationship between the proportion of patients aged over
75 years and some prescribing rates should be of great
interest. The proportion of patients aged over 75 years had
a negative relationship with statins and ACE inhibitors
and a positive association with aspirin. A number of stud-
ies found that older patients were much less likely than
younger patients to undergo a CABG or a PTCA[71,72] or
to receive a prescription for a statin [13,16,17,70], which
may result from the lack of research evidence on the effi-
cacy of statins in elderly populations or judgements about
likelihood of benefit based on age. Therefore, the negative
associations between the proportion of patients aged over
75 years and rates of ACE inhibitor and statin prescribing
are in line with other seemingly inequitable health care.
Although the proportion of patients aged over 75 years is
a proxy for CHD prevalence, it may not represent a useful
proxy of the potential to benefit from statins. However, it
may be suggested that prescribing rates for aspirin are
higher in this age group since they are more cost-effective
than statins [73]. Therefore, these drugs may be more
readily prescribed to patients for whom the benefits (both
clinical and cost-effectiveness) of statins have not been
studied.
Conclusion
Overall, this study has found that prescribing rates may be
explained (to differing degrees between primary care
trusts (PCTs) and between drug groups) by a mixture of
health care need indicators (HCNIs). Whilst prescribing
rates were generally positively related to the rates of hos-
pital procedures and diagnoses, they were also negatively
associated with proxies of deprivation and ethnicity and
with the proportion of patients aged over 75 years. How-
ever, the relatively low R2 values reveal a large amount of
unexplained variation in prescribing rates. Indeed, even
with the models for aspirin and all CHD drugs, there is
still around 50 per cent of unexplained variation in pre-
scribing rates.
This study cannot be used to infer inequitable prescribing
by GPs, since the lower prescribing rates in areas with high
proportions of South Asian and deprived groups may be
due to lower utilisation of primary health care services due
to social, economic or cultural barriers [74,75]. Therefore,
further work needs to be undertaken in areas of depriva-
tion and with high proportions of minority ethnic groups
in order to understand the reasons for the low prescribing
rates and ultimately to make CHD prescribing commen-
surate with healthcare need. In addition, the HCNIs used
in this study are proxies for healthcare need, and may not
reflect actual healthcare need. Therefore, future studies
may attempt to verify our findings by using either morbid-
ity or mortality data gathered from GP practices.
Whilst the clinical and epidemiological data on these
CHD drugs has allowed for the development of evidence-Page 8 of 11
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paper suggests that in practice, actual prescribing rates
may not be related to health care need. Further research
needs to concentrate on verifying or falsifying these claims
on a more micro-level analysis (eg clinical audit in specific
GP practices identified in the study) and on exploring the
reasons why such a relationship exists (e.g. qualitative
studies with GPs, practice nurses and patients in the iden-
tified GP practices). In addition, more work is required to
understand the differences between PCTs in terms of the
explanatory power of the regression models (i.e. much
more of the variation in prescribing rates were explained
in PCT2 than any other PCT). Such a strategy may enable
educational tools to be developed which would facilitate
more evidence-based prescribing, but may also identify
particular patient groups who do not present symptoms
of CHD (ie unmet need) and therefore may require edu-
cational outreach or targeted screening in order to
increase their consultations and ultimately prescribing to
these groups. Although we have focussed on drugs used in
the prevention of CHD, a similar approach may be taken
across different therapeutic groups of drugs, in different
health care settings and in different countries in order to
generate more rounded, grounded and extensive evidence
on the equity of prescribing in general.
Appendix A – List of drugs used in this study
• Aspirin (75 mg)
• Bendrofluazide1 (2.5 mg)
• Statins (Atorvastatin, Cerivastatin, Fluvastatin, Pravasta-
tin, Simvastatin)
• ACE inhibitors2 (Captopril, Enalapril, Lisinopril, Rami-
pril, Trandolapril)
• Beta-blockers3 (Atenolol, Co-tenidone4)
1 In some countries, this may also be known as (among
other names) Neo-NaClex, Bendroflumethiazide, Apri-
nox, Berkozide, Naturetin, Pluryl, Polidiuril, Salural,
Urizde.
2 The 5 ACE inhibitors represent the majority of prescrib-
ing for all ACE inhibitors
3 Atenolol represents the majority of prescribing of all
beta-blockers
4 Co-tenidone is a combination product containing both
a beta-blocker (atenolol) and a diuretic (chlorthalidone).
Appendix B – List of health care needs indicators 
(HCNIs) developed during the study
• Proportion of patients aged between 55 and 74 years
• Proportion of patents aged over 75 years
• Proportion households with no car
• Proportion males who are economically inactive
• Townsend Score
• Proportion of households receiving council tax benefits
• Proportion unemployment
• Index of Multiple Deprivation
• Income Deprivation Index
• Low Income Scheme Index (LISI) score
• Standardise mortality rate (SMR) for CHD under 75
years
• 6-year crude rate of coronary artery bypass grafts
(CABGs) per 1000 patients
• 6-year crude rate of percutanious transluminal angi-
oplasty (PTCAs) per 1000 patients
• 6-year crude rate of coronary angiograms per 1000
patients
• 6-year crude rate of CHD hospital procedures (CABGs +
PTCAs + angiograms) per 1000 patients
• 6-year crude rate of CHD hospital diagnoses per 1000
patients
• 6-year crude rate of CHD prevalence (diagnoses + proce-
dures) per 1000 patients
• Regionally specific prevalence, age and sex standardised
prescribing units per patient over 35 years (PASS-PUs)
• Proportion of population defining themselves as 'non-
white'
• Proportion of population defining themselves as 'South
Asian'
• Proportion of population over 30 with a limiting long-
term illness (LLI)Page 9 of 11
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• Proportion of households with more than 2 cars
• Access Deprivation Index
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